Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.

The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PRP Injections for Genitourinary Syndrome of Menopause

NCT06028009

PRP Sexual Function Disturbances Genitourinary Syndrome of Menopause +2 more

ACTIVE_NOT_RECRUITING NA

Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit

NCT06425978

Genitourinary Syndrome of Menopause

RECRUITING PHASE4

Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause

NCT05571527

Genitourinary Syndrome of Menopause

RECRUITING NA

The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy

NCT06514586

Vaginal Atrophy Genitourinary Syndrome of Menopause Vulvar Atrophy

NOT_YET_RECRUITING PHASE3

Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause

NCT05263102

Menopause Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause Platelet-rich Plasma Estrogen Replacement Therapy Vaginal Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genital urinary symptoms of menopause

Menopause for one year, or age above 45 with symptoms of GSM

Vaginal estrogen supplement

Intervention Type DRUG

Daily vaginal estrogen supplement, then twice per week. Continue for three months.

Platelet-rich plasma injection

Intervention Type PROCEDURE

Monthly platelet-rich plasma injection for three months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaginal estrogen supplement

Daily vaginal estrogen supplement, then twice per week. Continue for three months.

Intervention Type DRUG

Platelet-rich plasma injection

Monthly platelet-rich plasma injection for three months

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with menopause
* Patients with symptoms of genitourinary syndrome of menopause

Exclusion Criteria

* Genitourinary bleeding or infection without definitive diagnosis
* Coagulopathy
* Allergy to medication or therapy related with the treatment
* Chronic disease that might influence outcome
* Using medication that might influence outcome in 30 days
* Using hormone or steroid within 8 weeks

Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No